BRAF and skin squamous cell carcinoma: The addition of MEK inhibitors to BRAF inhibition could delay the development of this acquired resistance by blocking ERK signaling as well as prevent paradoxical MAPK pathway activation in the development of secondary squamous cell skin cancers, hence the development of combination treatments [3].